Mirtazapine Sandoz 45 (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonizing 5‑HT2 and 5‑HT3 serotonin receptors while strongly inhibiting H1 histamine receptors. This combined effect enhances noradrenergic and serotonergic neurotransmission, producing antidepressant and anxiolytic actions.

The appropriate dose of Mirtazapine Sandoz 45 is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage adjustments are made according to professional guidelines and patient needs.

Safety data for mirtazapine in pregnancy and lactation are limited, and the product’s pregnancy category is listed as unknown. Clinicians should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing patients.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its combined α2‑adrenergic antagonism and potent H1‑receptor blockade. This profile often results in pronounced sedation and appetite stimulation, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about these effects.

Mirtazapine Sandoz 45 tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep out of reach of children and do not use after the expiry date.

The medication is taken orally, usually once daily in the evening due to its sedative effect. Tablets should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include the potential for agranulocytosis, severe neutropenia, leukopenia, seizures, and heightened suicidal thoughts, particularly during early treatment or dosage changes. Prompt medical attention is required if any of these symptoms occur.

Mirtazapine is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) within 14 days, those with known hypersensitivity to the drug, and individuals with severe hepatic impairment where the risk outweighs benefit. Clinicians should also avoid use in patients with uncontrolled cardiovascular disease without careful monitoring.